病前残疾的急性缺血性卒中患者的溶栓治疗:一项Meta分析
该系统综述与Meta分析纳入8篇文章共103 988例患者,评估病前残疾(改良Rankin量表评分3-5分)的急性缺血性卒中患者接受静脉溶栓的结局。病前残疾患者接受静脉溶栓后恢复至基线功能的比值比为7.26(95%CI 2.51-21.02),症状性颅内出血与死亡率与未溶栓者无显著差异;与无病前残疾者相比,恢复至基线功能及症状性颅内出血无显著差异,但死亡率后者为38.2%对12.6%。
要点
- 病前残疾患者接受静脉溶栓恢复至基线功能的比值比为7.26(95%CI 2.51-21.02)。
- 病前残疾溶栓与未溶栓者症状性颅内出血和死亡率无显著差异。
- 病前残疾者死亡率38.2%,无病前残疾者12.6%。
核心结论
- 病前残疾患者使用静脉溶栓与更好的结局相关,且症状性颅内出血或死亡率无统计学显著增加的风险。
- 与无病前残疾者相比,恢复至基线功能或症状性颅内出血无显著差异。
- 需要高质量数据比较病前残疾患者接受与未接受治疗的情况以阐明该问题。
研究设计与样本
- 系统综述与Meta分析,遵循观察性研究Meta分析指南。
- 纳入报告病前残疾(改良Rankin量表评分3-5分)的急性缺血性卒中患者接受静脉溶栓的研究,对照为未治疗患者或无病前残疾的治疗患者。
- 共纳入8篇文章,涉及103 988例患者。
主要发现
- 病前残疾患者接受静脉溶栓恢复至基线功能的比值比为7.26(95%CI 2.51-21.02),优于未接受静脉溶栓者。
- 病前残疾患者接受与未接受静脉溶栓者死亡率及症状性颅内出血率无显著差异,但静脉溶栓组症状性颅内出血数量上更多。
- 病前残疾与无病前残疾患者恢复至基线功能的比值比为1.46(95%CI 0.75-2.83),无显著差异。
- 病前残疾与无病前残疾患者症状性颅内出血率无显著差异。
- 病前残疾患者死亡率38.2%,无病前残疾患者12.6%,前者为后者的3倍。
关键数值与推荐
- 病前残疾定义为改良Rankin量表评分3-5分。
- 主要结局为90天时恢复至病前残疾状态。
- 次要结局包括90天良好功能结局(改良Rankin量表评分0-2分或恢复至病前改良Rankin量表评分)的率与比值比、症状性颅内出血及90天死亡率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要高质量数据比较病前残疾患者接受与未接受治疗的情况以阐明该问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized controlled trials for the use of alteplase in acute ischemic stroke have excluded or had little representation of patients with prestroke disability, and the benefit of alteplase in this population remains uncertain. We performed a systematic review and meta-analysis to examine the outcomes of thrombolysis in patients with premorbid disability. METHODS: We performed a systematic review in accordance with the Meta-Analysis of Observational Studies in Epidemiology guidelines and retrieved studies reporting intravenous thrombolysis (IVT) in patients with prestroke disability (modified Rankin Scale score, 3-5) with acute ischemic stroke, either compared with untreated patients or treated patients without premorbid disability. The primary outcome was the return to premorbid disability at 90 days. Secondary outcomes included rate and odds ratio of favorable functional outcome at 90 days (modified Rankin Scale score 0-2 or return to premorbid modified Rankin Scale), symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. RESULTS: Eight articles were included involving 103 988 patients. Patients with disability treated with IVT had better odds of returning to baseline function compared with those who did not receive IVT (odds ratio, 7.26 [95% CI, 2.51-21.02]). Mortality and rates of sICH were not significantly different between patients with disability treated with IVT and those not treated, although there were numerically more sICHs in the IVT group. Return to baseline function was not significantly different between patients with and without prestroke disability (odds ratio, 1.46 [95% CI, 0.75-2.83]). The rates of sICH were not significantly different in patients with and without premorbid disability. However, mortality was 3× higher in patients with premorbid disability than in those without premorbid disability (38.2% versus 12.6%). CONCLUSIONS: The use of IVT in patients with disability was associated with better outcomes compared with patients who did not receive IVT without statistically significant added risks of sICH or mortality. When compared with those without disability, there was no significant difference in the return to baseline function or sICH. High-quality data comparing treated versus untreated patients with premorbid disability are needed to clarify this issue. REGISTRATION: URL: https://www.crd.york.ac.uk/PROSPERO/; Unique identifier: CRD42021240499.
引用
- Beland B, Bala F, Ganesh A, et al. Thrombolysis for Acute Ischemic Stroke in Patients With Premorbid Disability: A Meta-Analysis. Stroke. 2022. PMID: 35686556. doi:10.1161/STROKEAHA.121.038374
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。